Peptide Synthesis Market - Emerging Trends & Global Future Forecasts

The overall peptide synthesis market was valued at USD 292.4 million in 2017 and is projected to reach USD 426.4 million by 2023, at a CAGR of 6.5% during the forecast period.

Market growth can be attributed to increasing use of peptides in pharmaceutical drugs, increase in research activities and availability of funding for R&D, and the development of advanced peptide synthesizers. The base year considered for the study is 2017, and the forecast has been provided for the period between 2018 and 2023.

By technology, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023

Based on technology, the peptide synthesis market has been segmented into solid-phase synthesis, liquid-phase synthesis and recombinant technology. In 2017, solid-phase synthesis is expected to grow at the highest CAGR during 2018-2023. Solid-phase synthesis is associated with a number of advantages, such as ease of operation, easy purification, short production cycles, high-level automation, and synthesis capabilities of long peptides in small quantities of amino acids. Such advantages are driving the growth of the solid-phase synthesis segment.

Download PDF Brochure@
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=158927365

Pharmaceutical & biotechnological companies are expected to dominate the peptide synthesis market in 2017

Based on end users, the peptide synthesis market is segmented into pharmaceutical & biotechnological companies, contract development and manufacturing organizations, and academic and research institutes. In 2017, pharmaceutical & biotechnological companies accounted for the largest market share due to increasing number of research projects in genomics, molecular biology, and related areas; growing application areas of peptides in drug discovery, therapeutics, and research; and substantial R&D investments.

Major Market Developments:

# In 2018, CEM Corporation launched the Liberty PRIME, automated microwave peptide synthesizer.

# In 2017, Merck acquired Grzybowski Scientific Inventions (GSI) (US). This acquisition helped the company to expand its chemical synthesis portfolio.

# In 2015, Merck acquired Sigma-Aldrich Corporation (US). This acquisition strengthened Merck’s Life Science segment. Sigma-Aldrich’s SAFC Commercial business is now a part of Merck’s Life Science segment.

APAC is expected to grow at the highest CAGR during the forecast period.

Global peptide synthesis market has been studied for North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. APAC is expected to grow at the highest CAGR in the peptide synthesis market, primarily due to the increasing investments by pharmaceutical and biotechnology companies and rising R&D activities in the region.

Global Leaders:

The prominent players in the peptide synthesis market are GenScript Biotech Corporation (China), AAPPTec (US), Bachem (Switzerland), AnaSpec (US), Biotage (Sweden), CEM Corporation (US), Gyros Protein Technologies (Sweden), Advanced ChemTech (US), Merck KGaA (Germany) and New England Peptide, Inc (US). Product launches and agreements, partnerships and collaborations were the major strategies adopted by these payers to maintain their positions in the peptide synthesis market.

Request Sample Pages@
https://www.marketsandmarkets.com/requestsampleNew.asp?id=158927365

GenScript Biotech Corporation

GenScript accounted for the largest share of the market in 2017. The company has a broad product/services portfolio in peptide synthesis market and focuses on research and development activities to enhance its offerings. For Instance, in 2016 the company’s research and development expenses were approximately USD 9.5 million, 8.3% of the total revenue.

Merck KGAA

Merck held the second position in the peptide synthesis market in 2017. The company offers a broad product portfolio of peptide synthesis reagents and custom peptide synthesis services in the market. To leverage growth opportunities in the peptide synthesis market, Merck focuses on adopting organic as well as inorganic growth strategies.

Bachem holdings

Bachem is an important player in the peptide synthesis market in 2017. The company offers catalog products that include amino acids, resins, linkers, & reagents. It also offers custom synthesis services in the market. The company aims on broadening its geographic reach by investing in strategic acquisitions, agreements, and collaborations.